# Macitentan to Prevent PRVO

> **NCT05946811** · PHASE3 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Pulmonary Embolism

## Interventions

- **DRUG:** Macitentan 10mg

## Key facts

- **NCT ID:** NCT05946811
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was cancelled by funding agency before starting enrollment.
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05946811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05946811, "Macitentan to Prevent PRVO". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05946811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*